Category Archives: Drug Companies

With over 1.5 million drug and medical device related injuries each year, consumers are forced to take legal action. Find out if you have a lawsuit. Read news stories about dangerous medical devices and prescription drugs, health studies and pharmaceutical litigation.

Will California finally have a statewide standard for the sale of legal marijuana by 2018?

November’s law legalizing recreational weed has added a new set of challenges for regulation

Marijuana for medical use has been legal in California since 1996, but efforts to regulate it like a normal product have been elusive.

For nearly two decades the production, distribution, sale and taxation of cannabis has operated through a patchwork of local rules that can differ from one city or county to the next. What one grower or pot dispensary does in one part of the state could be illegal in another, from the number of plants producers can grow to whether or not cannabis-based edibles require warning labels.

Now that voters have approved the sale of marijuana for recreational use through November’s Proposition 64 referendum, officials involved with working out regulations are scrambling. They must establish statewide rules before the start of next year, when licenses are supposed to become available for the sale of recreational-use marijuana.

Some are doubtful that state policymakers will have everything in order by then.

“They can’t get it together about what they want the laws to be,” Alicia Darrow, chief operations manager of Blum Oakland, a 13-year-old Bay Area medical marijuana dispensary, told Salon. “I’ll be shocked if it goes live in 2018.”

The problem, she said, is that Prop. 64 threw a wrench into regulators’ efforts that began in October 2015 after the passage of Assembly Bill 266, the state’s first successful attempt to pass a law regulating medical marijuana.

Prop. 64 and AB 266 have considerable differences in the way marijuana is regulated that must be worked out. For example, AB 266 requires a small number of third-party companies to control distribution and oversee testing for pesticide contamination, something dispensaries argue is unnecessary and would increase costs. Another unanswered question pertains to how dispensaries that sell medical-use marijuana and the more heavily taxed recreational-use weed will be required to track and manage their inventories and sales. Under Prop. 64,  dispensaries must have two separate inventories and tracking systems.

“It’s a big job, but we’re working hard and have every intention of meeting our goals,” Alex Traverso, a spokesman for the state’s Bureau of Medical Cannabis Regulation, said in an email to Salon. “The work we’ve done on regulations for medical cannabis have given us a great start.”

Meanwhile established growers, many of them mom-and-pop operations, are worried about being muscled out by bigger, well-financed ventures backed by deep-pocketed investment groups that are chasing the potential for big gains in the years to come. California’s medical marijuana business generated nearly $2.7 billion in sales in 2015 and that’s expected to balloon to $6.45 billion annually by 2020, including sales from recreational-use marijuana, according to cannabis industry investment network Arcview.

Read Full – http://www.salon.com/2017/02/05/will-california-finally-have-a-statewide-standard-for-the-sale-of-legal-marijuana-by-2018/

6 pharma executives face criminal charges for alleged fentanyl racketeering scheme

Six pharmaceutical executives who worked for Chandler, Ariz.-based Insys Therapeutics were arrested Thursday on charges that they led a nationwide conspiracy to bribe clinicians to unnecessarily prescribe fentanyl-based pain medication, according to the Department of Justice.

The government claims the executives conspired to bribe physicians and medical practitioners in several states, many of whom worked in pain clinics, to prescribe their pain medication called Subsys. This narcotic contains fentanyl, a highly addictive synthetic opioid, and is intended to treat cancer patients suffering intense episodes of breakthrough pain.

In exchange for kickbacks and bribes, practitioners allegedly wrote large numbers of prescriptions for patients, few of whom were diagnosed with cancer. The indictment also alleges the former Insys executives conspired to defraud health insurers that showed reluctance to approve payment for Subsys when it was prescribed to non-cancer patients. The defendants allegedly did so by establishing a “reimbursement unit” that obtained prior authorization directly from insurers and pharmacy benefit managers.

Here are the names of the defendants, all of whom are no longer employed by Insys Therapeutics, along with the respective charges they face:

  • Michael Babich, former president and CEO: conspiracy to commit racketeering, conspiracy to commit wire and mail fraud and conspiracy to violate the Anti-Kickback Law
  • Alec Burlakoff, former vice president of sales: Racketeer Influence and Corrupt Organizations Act conspiracy, mail fraud conspiracy and conspiracy to violate the Anti-Kickback Law
  • Richard M. Simon, former national director of sales: RICO conspiracy, mail fraud conspiracy and conspiracy to violate the Anti-Kickback Law
  • Sunrise Lee, former regional sales director: RICO conspiracy, mail fraud conspiracy and conspiracy to violate the Anti-Kickback Law
  • Joseph A. Rowan, former regional sales director: RICO conspiracy, mail fraud conspiracy and conspiracy to violate the Anti-Kickback Law
  • Michael J. Gurry, former vice president of managed markets: RICO conspiracy and wire fraud conspiracy

Criminal charges are rarely pressed in cases involving pharmaceutical companies, and several agents noted the severity of the charges in statements.

Full Read – http://www.beckershospitalreview.com/legal-regulatory-issues/6-pharma-executives-face-criminal-charges-for-alleged-fentanyl-racketeering-scheme.html

Legal Weed Is Hurting Beer Sales

It would appear that citizens of states with legal marijuana are switching out their beers for joints: A study from research firm Cowen & Company into the beer industries of Washington, Oregon, and Colorado asserts that those states’ beer industries are “underperforming.”

Craft beer industry news site BrewBound has some of the report’s details. “Domestic brewers” (that is, Big Beer) have seen the largest drops, with so-called premium brews (Coors Light, Bud Light) going down 4.4 percent in terms of the volume being sold. Economy brews (the regular, “non-fancy” forms of mainstream beers such as Budweiser or Coors) fell 2.4 percent.

Craft beer isn’t totally immune. The report suggests craft beer continues to grow in these three states (all of which are known for their robust microbrewing scenes), but those smaller breweries aren’t doing as well as their peers in other parts of the nation. However, the U.S. craft brewing scene was already slowing down, so that’s not entirely the fault of cannabis.

The epicenter of this trading-beer-for-weed phenomenon has been Denver, where beer volumes dropped by 6.4 percent Strangely, the report notes that import beers are relatively unaffected, indicating that lighting up a joint and drinking a Corona may be a more popular pastime.

Since only three states were studied this perhaps isn’t the most definitive look into the trend — but as marijuana goes on sale in several more states in the near future, there will be plenty of opportunities to see what legal weed might do to the beer industry.

sourced from – http://www.eater.com/2016/12/5/13847656/legal-pot-beer-sales-down

DEA raids colossal fentanyl operation. Could produce thousands of pills per hour.

By Ben Guarino

In one of the largest drug busts in Utah history, federal agents seized synthetic opioids in bulk and cash by the bagful on Tuesday. The home the agents raided contained a “pill press,” which they considered to be the source of thousands, possibly millions, of fentanyl pills. The drug producers falsely labeled the pills as Xanax or oxycodone and distributed the capsules in part by mail across the United States.

Multiple federal agencies, including the Drug Enforcement Administration and the National Guard, as well as the Internal Revenue Service, surrounded a house located in the city of Cottonwood Heights, in Salt Lake County. Authorities also searched another home, which the Salt Lake Tribune described as a “stash location.” At the stash location alone, the Tribune reported that authorities found 70,000 pills disguised as oxycodone and another 25,000 as fake Xanax.

Witnesses likened the scene at Cottonwood Heights to something “out of a science fiction movie,” as ABC4 Utah News put it, because agents donned oxygen tanks and protective gear before entering the home. Agencies were concerned that skin contact with fentanyl powder, which was reportedly present throughout the house, posed a danger.

Full Read – https://www.washingtonpost.com/news/morning-mix/wp/2016/11/23/dea-raids-colossal-fentanyl-operation-in-one-of-the-largest-drug-busts-in-utah-history/

Canada’s Top Pharmacy Chain Wants to Sell Medical Marijuana

By  | 

Canada’s biggest pharmacy chain is hoping to be the first in the country to sell legal medical marijuana over the counter. Shoppers Drug Mart has confirmed that it applied to the Canadian government earlier this year to become a licensed medical marijuana distributer.

In email statement Tuesday, Shoppers Drug Mart spokeswoman Tammy Smitham confirmed the news adding, “We have no intention of producing medical marijuana, but we do want the ability to dispense medical marijuana to our patients in conjunction with counseling from a pharmacist.”

Under Canadian federal law, patients with prescriptions are only able to purchase medical marijuana directly from one of a few dozen licensed producers. Producers are required to securely ship pot directly to the patient by mail order only.

“We believe that allowing medical marijuana to be dispensed through pharmacy would increase access, safety, quality and security for the thousands of Canadians who use the drug as part of their medication therapy,” explained Smitham. “We are hoping that the Government of Canada will revise the current regulations to allow for the dispensing of medical marijuana at pharmacy.”

Canada currently has an exceptionally large number of medical marijuana users; experts estimate that there are approximately 80,000 to 90,000 registered marijuana patients in the country.

In August, the Canadian Pharmacist Association argued in favor of clinical oversight from pharmacists to minimize harms associated with use of all forms of marijuana in its submission to the federal task force studying marijuana legalization and regulation.

Full Article – http://lawstreetmedia.com/blogs/cannabis-in-america/canadas-top-pharmacy-chain-wants-sell-medical-marijuana/